Patents Issued in May 2, 2024
-
Publication number: 20240140892Abstract: The ethanol synthesis catalyst is a catalyst for synthesizing ethanol from carbon dioxide, and includes at least one carrier selected from the group consisting of ZrO2, Al2O3, and TiO2; Fe and Cu supported on the carrier; and Na and/or K supported on the carrier. In one embodiment, the catalyst including iron oxide and copper oxide as the Fe and Cu supported on the carrier can be used, hydrogen can be supplied to the catalyst to reduce iron oxide and copper oxide, and a reaction gas containing CO2 can be supplied to the catalyst after reduction to obtain ethanol from CO2.Type: ApplicationFiled: April 27, 2021Publication date: May 2, 2024Applicant: Toyo Tire CorporationInventors: Norihiko Nakamura, Noritatsu Tsubaki, Guohui Yang
-
Publication number: 20240140893Abstract: The present disclosure provides high-grade ethanol production systems and methods that increase energy efficiency as compared to typical systems and methods by minimizing undesired acetal formation. The provided ethanol production method may include a low boilers removal distillation column and/or a stripper column constructed to simultaneously remove at least a portion of the acetaldehyde and at least a portion of the acetal from a feed stream in the presence of water. In some aspects, a low boilers removal process may be followed by a water removal process, which may be followed by a high boilers removal process. Acidity (e.g., carbon dioxide) may also be removed from a feed stream prior to or during the low boilers removal process. By minimizing acetal production, the provided method minimizes the amount of energy that is required to remove acetal when producing high-grade ethanol.Type: ApplicationFiled: July 7, 2023Publication date: May 2, 2024Applicant: Whitefox Technologies LimitedInventors: Virginia Andrade, Stephan Blum, Thiago Righi, Jin Ming Zhou
-
Publication number: 20240140894Abstract: Provided is method of treating a product of a chemical process, such as an amino acid or a nucleoside, the method comprising adding the product to a solvent such as propanol in a vessel to obtain a mixture, stirring the mixture, filtering the mixture so as to separate the product from the solvent and drying the filtered product.Type: ApplicationFiled: September 27, 2023Publication date: May 2, 2024Applicant: Illinois Tool Works Inc.Inventors: Raul Ondono Molina, Hector Torralvo Martin, Guillem Fernandez Freixes, Laura Martin Sanchez
-
Publication number: 20240140895Abstract: The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.Type: ApplicationFiled: August 23, 2019Publication date: May 2, 2024Applicant: XENIOPRO GmbHInventors: Viktoria REINMÜLLER, Roman MARTY, Olivier WAGNIÈRES, Jean-Baptiste GUALTIEROTTI, Verena KÜPPERS
-
Publication number: 20240140896Abstract: The present invention relates to a process for purifying a fermentation must (M), obtained via a biotechnological process, comprising biomass and vanillin or derivatives thereof, said purification process comprising: (a) a step of separating the biomass of a fermentation must (M) from an aqueous stream (A1) comprising vanillin or derivatives thereof, (b) at least one step of liquid/liquid extraction of the aqueous stream (A1) comprising vanillin or derivatives thereof, said extraction step allowing the separation of an aqueous stream (A2) and an organic stream (O1) comprising vanillin or derivatives thereof, (c) at least one step of concentrating the organic stream (O1) to obtain an organic stream (O2) in which compounds with a boiling point lower than that of vanillin or derivatives thereof are separated from said organic stream (O1), (d) at least one step in which compounds with a boiling point higher than that of vanillin or derivatives thereof are separated from an organic stream (O2) comprising vanillType: ApplicationFiled: March 14, 2022Publication date: May 2, 2024Applicant: SPECIALTY OPERATIONS FRANCEInventors: Talsida Zougmore, Rachid Djillali, Laurent Garel
-
Publication number: 20240140897Abstract: The present invention relates to a co-crystal of coenzyme QH and nicotinamide, a preparation method therefor and the use thereof. Compared with the existing coenzyme QH, the co-crystal has a higher melting point and superior stability. The preparation method for the co-crystal of coenzyme QH is simple, easy to control and good in terms of reproducibility. The present invention greatly improves the use convenience of coenzyme QH, saves costs during storage, transportation and use, and broadens the application range of coenzyme QH.Type: ApplicationFiled: March 7, 2022Publication date: May 2, 2024Inventors: Xuefeng MEI, Qi ZHANG, Junjie BAO, Liye LU
-
Publication number: 20240140898Abstract: The invention relates to a process for the continuous synthesis of a compound of formula (II) Br—(CH2)n+2—COOR, comprising a stage consisting of: (a) the hydrobromination of a compound of formula (I) CH2?CH—(CH2)n—COOR: where, in the formulae (I) and (II), n is an integer of between 7 and 9, and R is chosen from H or a linear or branched alkyl radical comprising from 1 to 10 carbon atoms, in particular methyl, ethyl, isopropyl or propyl, with HBr in the presence of a radical initiator and of at least one solvent; said process being characterized in that the reaction is carried out in the absence of benzene and of toluene and in that, in stage (a), the HBr is injected into the reaction mixture in the gaseous form and in stoichiometric excess.Type: ApplicationFiled: July 9, 2021Publication date: May 2, 2024Applicant: ARKEMA FRANCEInventors: Jean-François DEVAUX, Cyrille LE TOULLEC, Alain CAMBON
-
Publication number: 20240140899Abstract: Systems and methods for enriching an organic acid from a fermentation broth containing residual color, salts, and carbohydrates using simulated moving bed (“SMB”) chromatography to produce a high purity organic acid extract is disclosed. One embodiment of the method purifies citric acid from a fermentation broth into two product streams: a first product stream rich in salt, color, and carbohydrate impurities, and a second product stream comprising an extract enriched in organic acid.Type: ApplicationFiled: November 1, 2023Publication date: May 2, 2024Applicant: AMALGAMATED RESEARCH LLCInventors: Lily Crane, Peter V. Ferrero
-
Publication number: 20240140900Abstract: A method for manufacturing methyltetrahydrophthalic anhydride is provided, which includes steps as follows. Maleic anhydride is added into a reactor. Piperylene is added into the reactor, so that the piperylene and the maleic anhydride undergo a first addition reaction. When a conversion rate of the maleic anhydride is more than 25%, the first addition reaction is completed. Isoprene is added into the reactor, so that the isoprene and the maleic anhydride undergo a second addition reaction to obtain a methyltetrahydrophthalic anhydride product. The methyltetrahydrophthalic anhydride product contains 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride.Type: ApplicationFiled: December 21, 2022Publication date: May 2, 2024Inventors: TE-CHAO LIAO, JUNG-JEN CHUANG, CHUNG-YU CHEN, JUNG-TSU WU
-
Publication number: 20240140901Abstract: Process for preparing potassium oxalate which process comprises contacting potassium formate with a base catalyst at a temperature of from 140 to 260° C. which base catalyst is a metal hydride.Type: ApplicationFiled: January 6, 2022Publication date: May 2, 2024Inventors: Gerardus Johannes Maria Gruter, Eric Schuler
-
Publication number: 20240140902Abstract: The present invention relates to a method for synthesising a pheromone of general formula selected from the group comprising compounds (I) and (I?), alone or in admixture: (I) (I?) comprising reacting (2E)-pentene-1,5-diyl diacetate with at least one Grignard reagent in the presence of a copper-based catalyst. The method according to the invention is particularly applicable to the selective synthesis of tomato leafminer (Tuta absolute) pheromone comprising: (3E,8Z,11Z)-tetradecatrien-1-yl acetate and (3E,8Z)-tetradecadien-1-yl acetate.Type: ApplicationFiled: February 11, 2022Publication date: May 2, 2024Applicant: MELCHIOR MATERIAL AND LIFE SCIENCE FRANCEInventors: Eric GAYON, Loic GUILLONNEAU, Olivier GUERRET
-
Publication number: 20240140903Abstract: The disclosure relates to a compound of formula wherein Y, X, Ra, Rb, R1 and R2 are defined herein, PVC compositions comprising the compounds disclosed herein, as well as methods for modulating properties of a PVC, including reducing or preventing the formation of observable gas checks in calendered films, or other mechanical properties such as tensile strength and/or glass transition temperature.Type: ApplicationFiled: December 16, 2021Publication date: May 2, 2024Inventors: Richard LEASK, Roya JAMARANI, Omar Garcia VALDEZ, Jim A. NICELL, Milan MARIC, Matthew HALLORAN, Kushal PANCHAL, Roozbeh MAFI
-
Publication number: 20240140904Abstract: A compound represented by the following formula (1): One of R1 and R2 is a methyl group, and the other is an unsubstituted phenyl group, and R1 and R2 are not bonded to each other and therefore do not form a ring structure. One of R3 and R4 is a methyl group, and the other is an unsubstituted phenyl group, and R3 and R4 are not bonded to each other and therefore do not form a ring structure. R11 to R18, and R21 to R28 are hydrogen atoms, provided that, one selected from R11 to R18 is a single bond bonded to *a, and one selected from R21 to R28 is a single bond bonded to *b. L1 and L2 are each independently a single bond, or a substituted or unsubstituted phenylene group.Type: ApplicationFiled: March 30, 2022Publication date: May 2, 2024Applicant: IDEMITSU KOSAN CO.,LTD.Inventors: Tasuku HAKETA, Shota TANAKA, Yusuke TAKAHASHI, Takuto FUKAMI, Tsukasa SAWATO
-
Publication number: 20240140905Abstract: The present invention relates to a leveler capable of efficiently filling the inside of via holes formed during the manufacturing process of a printed circuit board, and an electroplating composition comprising the same. When via holes on a substrate are filled with the electroplating composition according to the present invention, the via holes can be filled in a relatively short time while minimizing the formation of dimples or voids.Type: ApplicationFiled: June 27, 2023Publication date: May 2, 2024Inventors: Dea Geun KIM, Sung Wook CHUN, Bo Mook CHUNG, Nak Eun KO
-
Publication number: 20240140906Abstract: The present invention relates to a process for the solidification of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate, DHHB), wherein the process comprises the step of (a) applying a shear rate of less than 800 s?1 to liquid hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate and (b) adding seed crystals of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.Type: ApplicationFiled: March 1, 2022Publication date: May 2, 2024Inventors: Daniel Ruben SELZER, Eva KLEINMANN, Axel BINDER, Helmut KRONEMAYER, Philipp STAEHLE
-
Publication number: 20240140907Abstract: The present invention is an anthraquinone compound represented by formula (1) (in the formula. R1 represents a hydrogen atom, a C1-C12 linear or branched alkyl group, or a C1-C12 linear or branched alkoxy group, and R2 represents a substituent represented by: formula (a) (in formula (a), R3 represents a hydrogen atom, a C1-C8 linear or branched alkyl group, a C1-C8 linear or branched alkoxy group, or a substituent represented by —CH2OR4, where R4 represents a C1-C8 linear or branched alkyl group); or formula (b) (in formula (b). R5 represents a hydrogen atom, a C1-C8 linear or branched alkyl group, or a substituent represented by —CH2OR6, where R6 represents a C1-C8 linear or branched alkyl group)).Type: ApplicationFiled: April 11, 2022Publication date: May 2, 2024Inventors: Kohei Ohtani, Masakazu Shiraishi, Hitomi Muto, Saori Suzuki, Kanae Ogawa
-
Publication number: 20240140908Abstract: The present invention relates to (R)-4-[5-(4-chlorophenyl)-1-[2-(trifluoromethyl)-phenyl]pyrrol-2-yl]-N-[2-(dimethylamino)-ethyl]benzamide (+)-L-tartrate salt, methods for its preparation, pharmaceutical compositions containing it and its use in treating diseases such as cancer.Type: ApplicationFiled: September 23, 2021Publication date: May 2, 2024Applicant: SENTINEL ONCOLOGY LIMITEDInventors: Meriel Ruth MAJOR, Robert George BOYLE, Stuart TRAVERS, David Winter WALKER, Julian Scott NORTHEN, Stefania SANTONI
-
Publication number: 20240140909Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary system are disclosed. Certain heptamethine cyanines exhibit biliary system specificity and methods for in vivo visualization of a biliary system of a subject are provided. The methods may be for diagnostic purposes and/or for visualization of biliary systems during surgery.Type: ApplicationFiled: November 27, 2023Publication date: May 2, 2024Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and HumanInventors: Martin John Schnermann, Roger Rauhauser Nani
-
Publication number: 20240140910Abstract: The present invention addresses the problem of finding a method for reliably producing (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, wherein crystalline polymorphs can be controlled with industrially easy operations. Provided is a method for producing a crystalline form of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, the method comprising: step (a) for heating and dissolving (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride in a solvent including an alcohol-based solvent; step (b) for cooling the dissolved product of step (a) to a temperature, at which crystals of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride precipitate, to nucleate the crystals; step (c) for heating a mixture containing the crystals obtained by nucleation to a temperature at which only a specific crystalline form selectively remains; and step (d) for cooling the mixture heated in step (c) to obtain the crystalline form.Type: ApplicationFiled: October 15, 2020Publication date: May 2, 2024Inventors: Rei Otsuka, Kimiyoshi Annaka, Hikaru Mitani
-
Publication number: 20240140911Abstract: The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).Type: ApplicationFiled: December 18, 2023Publication date: May 2, 2024Applicant: Arena Pharmaceuticals, Inc.Inventors: Anthony C. Blackburn, Ryan O. Castro, Mark Allen Hadd, You-An Ma, Antonio Garrido Montalban, Jaimie Karyn Rueter, Lee Alani Selvey, Sagar Raj Shakya, Marlon Carlos
-
Publication number: 20240140912Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein is versatile polyene cyclization strategy that exploits conjugated ?-ionyl derivatives. Photomediated disruption of the extended ?-system within these chromophores unveils a contra-thermodynamic polyene that engages in a Heck-type cyclization to afford [4.4.1]-propellanes. The connectivity of overbred polycycles generated from this process is controlled by the position of the requisite C-Halide bond. Thus, compared to conventional biomimetic polyene cyclization, this approach allows for complete control of regiochemistry and facilitates incorporation of both electron-rich and electron-deficient (hetero)aryl groups. This strategy was successfully applied to the total synthesis of abietanes such as, for example, taxodione and salviasperanol, two isomeric abietane-type diterpenes that previously could not be prepared along the same synthetic pathway.Type: ApplicationFiled: March 30, 2023Publication date: May 2, 2024Inventors: James H. Frederich, Megan M. Solans
-
Publication number: 20240140913Abstract: The present invention relates to a process for preparation of Abediterol of the Formula (I) or its pharmaceutically acceptable salts, and intermediate compounds including the compound of the Formula (VII) by chiral sulfide mediated epoxidation. The process involves preparation of the intermediate compounds followed by preparation of Abediterol from the intermediate compounds. The compound Abediterol having the formula I is synthesized by various routes from the intermediate compound of Formula (VII). The process is cost effective and gives higher yield and better purity. The process of the present invention uses simple raw materials and reagents; and does not use hypertoxic materials.Type: ApplicationFiled: February 9, 2022Publication date: May 2, 2024Applicant: GBR LABORATORIES PRIVATE LIMITEDInventors: Pratap Reddy Gaddam, Samhitha Reddy Gaddam, Madaalasa Reddy Gaddam, Udaya Kumar Reddy Mosali
-
Publication number: 20240140915Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.Type: ApplicationFiled: September 20, 2023Publication date: May 2, 2024Inventors: Shota Kikuchi, Betty Lam, Jason Green, Don Rogness, David Weinstein, Larry Burgess, Benjamin Horning, Kelsey Lamb, Zachary Owyang, Robert Malmstrom
-
Publication number: 20240140916Abstract: Provided is a method for producing an azole derivative with less amount of a by-product. A method for producing an azole derivative represented by general formula (I) includes reacting an oxirane derivative with 4-amino-1,2,4-triazole under an acidic condition and deaminating the obtained compound to form the azole derivative represented by general formula (I), where R1 is a C1-C6-alkyl group or the like; X1 and X2 are each independently a halogen group or the like; and n is 1, 2, or 3.Type: ApplicationFiled: February 22, 2022Publication date: May 2, 2024Applicant: Kureha CorporationInventors: Kaito NAGAI, Ryo HARIGAE
-
Publication number: 20240140917Abstract: The invention relates to isoxazoline compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting growing plants and animals from attack or infestation by invertebrate pests, furthermore, to seed comprising such compounds.Type: ApplicationFiled: January 31, 2022Publication date: May 2, 2024Inventors: Nikolas Huwyler, Karsten Koerber, Erik Gilberg, Sunderraman Sambasivan
-
Publication number: 20240140918Abstract: A compound represented by formula (1) below, useful for treating cancer. In the formula, R1 and R3-R8 each independently represents a hydrogen atom or an alkyl group, R2 represents a hydrogen atom or a group represented by —ORa, R9 represents a group represented by —C(O)NRcRf, Ra, Re, and Rf each independently represents a hydrogen atom, an arylalkyl group that may have a substituent, or a heteroarylalkyl group.Type: ApplicationFiled: January 28, 2022Publication date: May 2, 2024Inventors: Isamu SHIINA, Motoyuki SHIMONAKA, Takatsugu MURATA, Yuuki OBATA, Toshirou NISHIDA, Koji OKAMOTO
-
Publication number: 20240140919Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.Type: ApplicationFiled: December 1, 2023Publication date: May 2, 2024Inventors: Robert A. Craig II, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Tottumkara
-
Publication number: 20240140920Abstract: The present invention relates to efficient synthetic processes useful in the preparation of uridine, which is useful in the production of nucleosides and nucleotides that may be active as antiviral agents, as well as compositions and methods thereof.Type: ApplicationFiled: December 17, 2021Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Tamas Benkovics, Anna Fryszkowska, Mark A. Huffman, Tetsuji Itoh, Kevin M. Maloney, John McIntosh, Grant S. Murphy
-
Publication number: 20240140921Abstract: There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.Type: ApplicationFiled: May 15, 2023Publication date: May 2, 2024Applicant: Betagenon ABInventors: Thomas EDLUND, Jacob WESTMAN
-
Publication number: 20240140922Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: August 22, 2023Publication date: May 2, 2024Inventors: Samuel Bartlett, Joseph D. Panarese, Sourav Ghorai, Nathaniel Thomas Kenton, Sean Rafferty, Jonathan Thielman, Peilin Xu, Bin Wang, William Cassels, Scott Mitchell, Yat Sun Or
-
Publication number: 20240140923Abstract: The present disclosure relates to the technical field of drug synthesis, and provides a method for preparing a key intermediate of ABT-737 and a method for preparing ABT-737. In the present disclosure, the compound having a structure represented by formula I is used as the starting material. The carboxyl group in the compound having a structure represented by formula I is first reduced to a hydroxyl group, followed by a vulcanization by a vulcanizing agent, and then an amination, a deprotection, a condensation, and a carbonyl group reduction, to obtain the key intermediate of ABT-737 having a structure represented by formula VI. Tert-butoxycarbonyl is used as the protecting group for the compound having a structure represented by formula I, and the subsequent intermediate containing the protecting group of tert-butoxycarbonyl is stable, and easy to be deprotected. This method is suitable for mass synthesis, with high product yield and low production cost, and thus has a good industrialization prospect.Type: ApplicationFiled: June 17, 2021Publication date: May 2, 2024Applicant: Xeon Biopharmaceutical LimitedInventors: Yanfei GU, Yao HE
-
Publication number: 20240140924Abstract: Provided are a glycidyl (meth)acrylate composition, which includes a phenolic polymerization inhibitor that is unlikely to deteriorate such that the glycidyl (meth)acrylate composition can be stably stored for a long period of time, and a method for suppressing deactivation of a phenolic polymerization inhibitor in a glycidyl (meth)acrylate resin composition. More specifically, provided are: a glycidyl (meth)acrylate composition including a glycidyl (meth)acrylate, a quaternary ammonium salt, and a phenolic polymerization inhibitor, wherein a content of the quaternary ammonium salt is 1.00 ppm or less; and a method for suppressing deactivation of a phenolic polymerization inhibitor in a glycidyl (meth)acrylate composition, including adjusting a content of a quaternary ammonium salt in the glycidyl (meth)acrylate composition to 1.00 ppm or less.Type: ApplicationFiled: January 19, 2022Publication date: May 2, 2024Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Michihiro YURI, Kouji SUZUKI, Shu SUZUKI
-
Publication number: 20240140925Abstract: A method for manufacturing a low-viscosity hardener is provided. The method includes the followings steps: providing a hardener crude product; and subjecting the hardener crude product and an alkaline catalyst to an isomerization reaction, so as to obtain the low-viscosity hardener. The hardener crude product contains 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride, and a weight ratio of the 3-methyltetrahydrophthalic anhydride to the 4-methyltetrahydrophthalic anhydride ranges from 7:3 to 3:7. A viscosity of the low-viscosity hardener ranges from 30 cps to 50 cps.Type: ApplicationFiled: January 11, 2023Publication date: May 2, 2024Inventors: TE-CHAO LIAO, JUNG-JEN CHUANG, CHUNG-YU CHEN, JUNG-TSU WU
-
Publication number: 20240140926Abstract: An organic electronic device includes an anthracene-based compound represented by formula (I) wherein Q is selected from groups represented by formula (A-1) and formula (A-2): X is O or S; each of R1, R2, and R3 is independently selected from —H, -D, a C1-C6 alkyl group, a phenyl group, a biphenyl group, a phenyl group substituted by a C1-C6 alkyl group, and a biphenyl group substituted by a C1-C6 alkyl group; each of L1 and L2 is independently selected from a single bond, a phenyl group, a biphenyl group, a phenyl group substituted by a C1-C6 alkyl group, and a biphenyl group substituted by a C1-C6 alkyl group; and * indicates a binding site.Type: ApplicationFiled: November 24, 2022Publication date: May 2, 2024Inventors: Ruifeng HE, Canjie WU, Yan LI, Jingyao SONG
-
Publication number: 20240140927Abstract: A 3-hydroxyadipic acid-3,6-lactone composition includes 3-hydroxyadipic acid-3,6-lactone, and 3 to 30 parts by weight of ?-hydromuconic acid with respect to 100 parts by weight of the 3-hydroxyadipic acid-3,6-lactone; and a method produces a 3-hydroxyadipic acid-3,6-lactone composition, the method including a step of heating 3-hydroxyadipic acid-3,6-lactone to obtain the 3-hydroxyadipic acid-3,6-lactone composition.Type: ApplicationFiled: March 11, 2022Publication date: May 2, 2024Inventors: Daijiro Tsukamoto, Kenji Kawamura, Katsushige Yamada
-
Publication number: 20240140928Abstract: This invention relates to a method for the continuous production of optically pure lactide comprising a first reactive distillation system, a second reactive distillation system, a main distillation system and the side-draw refluxer. For each of the four systems a novel horizontally top-mounted condenser is used in order to decrease its total pressure drop and thus reduce side-reactions associated with high bottom temperature. In addition, a wiped film evaporator, a short path evaporator or a combination thereof is utilized for the concentration of the purge stream from the second reactive distillation, in a purpose of removing the metal contaminants contained in the purge stream and depolymerizing the contained unconverted lactic acid oligomers to crude lactide, all of which give additional advantages for the lactide production.Type: ApplicationFiled: February 22, 2021Publication date: May 2, 2024Inventor: Jianjun SUI
-
Publication number: 20240140929Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.Type: ApplicationFiled: December 22, 2021Publication date: May 2, 2024Inventors: Xing DAI, Xianhai HUANG, Hong YANG, Zixing HAN, Haotao NIU, Jifang WENG, Zhe SHI, Yanqin LIU, Yueheng JIANG, Yaolin WANG
-
Publication number: 20240140930Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolase.Type: ApplicationFiled: September 29, 2023Publication date: May 2, 2024Applicant: NeuroPn Therapeutics Inc.Inventors: Ish Khanna, Sivaram Pillarisetti
-
Publication number: 20240140931Abstract: Tricyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein each variable is as defined in the description.Type: ApplicationFiled: January 28, 2022Publication date: May 2, 2024Inventors: Guangxiu DAI, Kun XIAO, Wei DENG
-
Publication number: 20240140932Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.Type: ApplicationFiled: June 15, 2023Publication date: May 2, 2024Inventors: QING XU, CARSTEN ALT, ZHE LI, SHAHUL NILAR, PETER MICHAEL RADEMACHER, CALVIN WESLEY YEE
-
Publication number: 20240140933Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A1 to A3 and n are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: November 20, 2023Publication date: May 2, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Fabian DEY, Dong DING, Xingchun HAN, Chungen LIANG, Hongtao XU, Ge ZOU
-
Publication number: 20240140934Abstract: The technical field of pharmaceuticals. Disclosed are a triazole derivative, a method for preparing same, and use thereof. The triazole derivative has a structure as shown in formula I, and the triazole derivative of the present invention can be used as a CRM1 inhibitor for preparing a medicament for treating a disease related to CRM1 activity.Type: ApplicationFiled: March 11, 2022Publication date: May 2, 2024Applicant: SHENZHEN JIKANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Yongqiang ZHU, Meng LEI, Hang MIAO, Xueyuan WANG
-
Publication number: 20240140935Abstract: Herein provides a non-covalent dimer cation of formula (A), a tautomer thereof, or a stereoisomer thereof. Herein provides a salt, which includes the cation of the present application and a first anion. Herein provides use of the cation of the present application or the salt of the present application in antioxidation, preparation of an antioxidant, preparation of a drug for inhibiting, reducing or reversing oxidative stress in human or animal cells, or preparation of a drug for treating an oxidative stress-associated disease or symptom, such as, use in preparation of a drug for treating non-alcoholic fatty liver disease.Type: ApplicationFiled: September 27, 2023Publication date: May 2, 2024Inventors: Zizhen ZHAO, Zhigang WANG
-
Publication number: 20240140936Abstract: The present invention relates to a method for the enantioselective preparation of a compound of formula (I).Type: ApplicationFiled: February 18, 2022Publication date: May 2, 2024Inventors: Fabio Bertozzi, Tiziano Bandiera, Francesco Berti, Alejandra Rodriguez Gimeno, Federico Sorano, Filippo Romoli, Francesco Calogero
-
Publication number: 20240140937Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: November 28, 2023Publication date: May 2, 2024Applicant: Pfizer Inc.Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
-
Publication number: 20240140938Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.Type: ApplicationFiled: December 17, 2021Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Jianming Bao, Chen Cheng, Faben A. Cruz, Yeon-Hee Lim, Cedric L. Hugelshofer, Jinlong Jiang, Victor W. Mak, Emma Helen Southgate
-
Publication number: 20240140939Abstract: Embodiments of the present disclosure relate to cyclooctatetraene containing dyes and their uses as fluorescent labels. Also provided are composition containing cyclooctatetraene. The dyes and compositions may be used in various biological applications, such as nucleic acid sequencing.Type: ApplicationFiled: September 28, 2023Publication date: May 2, 2024Inventors: Xiaolin WU, Benedict MACKWORTH, Madushani DHARMARWARDANA, Patrick MCCAULEY, Philip STACKHOUSE, Xiaohai LIU, Tao YAN, Krystle REISS
-
Publication number: 20240140940Abstract: Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1/Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.Type: ApplicationFiled: September 12, 2023Publication date: May 2, 2024Inventors: Steven Fletcher, Brandon Drennen
-
Publication number: 20240140941Abstract: Disclosed are a derivative of a 2,5-diketopiperazine compound, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed are a compound as represented by formula (I), a stereoisomer thereof, a tautomer thereof or a pharmaceutically acceptable salt thereof, or a solvate of any one of the aforementioned. The compound is new in terms of structure, and has good anti-tumor activity and water solubility.Type: ApplicationFiled: December 31, 2021Publication date: May 2, 2024Inventors: Wenbao William LI, Zhongpeng DING, Feifei LI, Lianghui XIE, Yun XU, Xinwen WANG
-
Publication number: 20240140942Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: June 21, 2023Publication date: May 2, 2024Inventors: Ben C. ASKEW, Richard W. HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS